Respiratory tract neoplasm
MONDO:0020641A benign or malignant, primary or metastatic neoplasm involving the respiratory tract.
Also known as: neoplasm of respiratory tract, neoplasm of the respiratory tract, neoplasm, respiratory tract, neoplasms, respiratory tract, respiratory system neoplasm, respiratory tract neoplasm, respiratory tract tumor, respiratory tract tumour
5577 clinical trials for this condition and its sub-types, 32 tagged with Respiratory tract neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Respiratory tract neoplasm
-
Lung neoplasm 1,367 trials · 4,039 incl. sub-types
10 sub-types
- Lung cancer 1,207 trials · 3,941 incl. sub-types Sub-types →
- Lung neuroendocrine neoplasm 21 trials · 540 incl. sub-types Sub-types →
- Lung benign neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Lung PEComa 0 trials · 1 incl. sub-types Sub-types →
- Pulmonary sulcus neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Langerhans cell histiocytosis specific to adulthood 0 trials Sub-types →
- Fibroma of lung 0 trials
- Hamartoma of lung 0 trials Sub-types →
- Lung germ cell tumor 0 trials
- Lung hilum neoplasm 0 trials Sub-types →
-
Nasopharyngeal neoplasm 37 trials · 226 incl. sub-types
3 sub-types
- Malignant tumor of nasopharynx 9 trials · 213 incl. sub-types Sub-types →
- Benign neoplasm of nasopharynx 0 trials
- Nasopharyngeal teratoma 0 trials
-
Laryngeal neoplasm 72 trials · 138 incl. sub-types
6 sub-types
- Larynx cancer 41 trials · 125 incl. sub-types Sub-types →
- Glottis neoplasm 3 trials · 12 incl. sub-types Sub-types →
- Supraglottis neoplasm 0 trials · 3 incl. sub-types Sub-types →
- Benign laryngeal neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Subglottis neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Laryngeal neuroendocrine neoplasm 0 trials Sub-types →
-
Pleural neoplasm 5 trials · 97 incl. sub-types
5 sub-types
- Pleural mesothelioma 28 trials · 86 incl. sub-types Sub-types →
- Pleural cancer 9 trials · 83 incl. sub-types Sub-types →
- Benign neoplasm of pleura 0 trials Sub-types →
- Neurilemmoma of the pleura 0 trials
- Pleural solitary fibrous tumor 0 trials Sub-types →
-
Bronchial neoplasm 20 trials · 38 incl. sub-types
5 sub-types
- Bronchus cancer 3 trials · 26 incl. sub-types Sub-types →
- Bronchial endocrine tumor 4 trials
- Bronchus adenoma 0 trials Sub-types →
- Endobronchial leiomyoma 0 trials
- Endobronchial lipoma 0 trials
-
Nasal cavity neoplasm 1 trial · 15 incl. sub-types
3 sub-types
- Nasal cavity cancer 5 trials · 14 incl. sub-types Sub-types →
- Benign neoplasm of nasal cavity 1 trial Sub-types →
- Nasal cavity inverting papilloma 0 trials
-
SMARCA4-deficient sarcoma of thorax 8 trials
-
Trachea neoplasm 2 trials · 5 incl. sub-types
2 sub-types
- Benign neoplasm of trachea 0 trials · 2 incl. sub-types Sub-types →
- Tracheal cancer 0 trials · 1 incl. sub-types Sub-types →
Most studied deeper sub-types
-
New combo shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if t…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo therapy shows promise for common lung cancer mutation
Disease control OngoingThis study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug combo aims to stop lung Cancer's return
Disease control OngoingThis phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable …
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…
Phase 1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy aims to stop lung cancer return after surgery
Disease control OngoingThis Phase III trial tests whether adding immunotherapy to standard chemotherapy after lung cancer surgery can delay or prevent the cancer from coming back. It enrolls 210 patients with stage IB-IIIA non-small cell lung cancer that was completely removed. Participants are randoml…
Phase 3 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Last-Resort drug access for rare lung cancer patients
Disease control Expanded access (ended)This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …
Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can doctor training boost lung cancer care in smaller cities?
Knowledge-focused OngoingThis study looks at whether educating doctors in small and mid-sized city hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted treat…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Robot-Assisted lung biopsy under the microscope: will it deliver?
Knowledge-focused OngoingThis study is tracking over 1,300 people who are having a lung biopsy or lesion localization with the Ion Endoluminal System, a robotic device. The goal is to see how often the device successfully gets a diagnosis and how often complications like a collapsed lung or bleeding occu…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC